Thyrocare Technologies Limited announced the outcome of its Board Meeting held on May 07, 2026. The Board recommended a final dividend of ₹7.00 per equity share for FY2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). This, combined with the interim dividend of ₹7.00 per share (₹2.33 post-bonus), brings the total dividend for FY2025-26 to ₹9.33 per equity share. The Board also approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as the Statutory Auditors for a term of five consecutive years, commencing from the conclusion of the 26th AGM (2026) until the 31st AGM (2031), replacing M/s. M S K A & Associates LLP. Additionally, M/s. Jitender Navneet & Co. was appointed as the Cost Auditors for FY2026-27. Key leadership changes were approved, including the re-appointment of Mr. Rahul Franklin Guha as Chairman, Managing Director & CEO for a further five-year term from May 4, 2027, to May 3, 2032. The Board also appointed Mr. Uday Patel Kadam and Mr. Gaurav Verma as Additional Directors (Non-Executive, Non-Independent) effective May 8, 2026. Concurrently, the Board noted the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah as Non-Executive, Non-Independent Directors, effective May 07, 2026, due to pre-occupation and other commitments. Furthermore, the Board approved an investment of up to ₹5.50 crore in equity shares of Think Health Diagnostics Private Limited, a wholly-owned subsidiary, to support its operations and capital expenditure. The Memorandum of Association (MOA) of the company was also approved for alteration, subject to shareholder approval, to align with the Companies Act, 2013, and broaden its scope in the healthcare and diagnostics ecosystem. The Board Meeting commenced at 3:35 PM and concluded at 5:40 PM.
